SEELOS THERAPEUTICS, INC.
SEEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SEEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2024.
Tracking 3 pipeline candidates · 2 clinical trials for SEELOS THERAPEUTICS, INC..
Run SEELOS THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SEELOS THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
2.8 months
OCF -$972K · Net income $2M
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is SEELOS THERAPEUTICS, INC.'s lead drug candidate?
SEELOS THERAPEUTICS, INC.'s most advanced tracked candidate is sls-002 (Phase 2) for Acute Suicidal Ideation and Behavior ("ASIB") in Major Depressive Disorder ("MDD").
Who is the CEO of SEELOS THERAPEUTICS, INC.?
Raj Mehra, Ph.D. is the chief executive officer of SEELOS THERAPEUTICS, INC. (SEEL).
What therapeutic areas does SEELOS THERAPEUTICS, INC. focus on?
SEELOS THERAPEUTICS, INC. develops therapies across Rare Disease, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.